Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved quizartinib as a treatment option for the maintenance treatment of adult patients with FLT3-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.

This is written in the approval document as:

As a monotherapy for the maintenance treatment of adult patients with FLT3-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.

Reimbursement

CDS

Citation

Quizartinib Maintenance Therapy, 2026, version number 2, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/7019/888_Quizartinib_Maintenance.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2025-02-01	Health Service Executive	Indication approved for reimbursement.